Invention Grant
- Patent Title: Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use
-
Application No.: US15508851Application Date: 2015-09-03
-
Publication No.: US10576141B2Publication Date: 2020-03-03
- Inventor: Ariane Volkmann , Robin Steigerwald , Hubertus Hochrein , Ulrike Dirmeier , Henning Lauterbach , Jürgen Hausmann Hausmann
- Applicant: Bavarian Nordic A/S
- Applicant Address: DK Kvistgaard
- Assignee: Bavarian Nordic A/S
- Current Assignee: Bavarian Nordic A/S
- Current Assignee Address: DK Kvistgaard
- International Application: PCT/EP2015/070161 WO 20150903
- International Announcement: WO2016/034678 WO 20160310
- Main IPC: A61K39/12
- IPC: A61K39/12 ; C12N7/00 ; C07K14/08 ; A61K39/00
Abstract:
The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.
Public/Granted literature
- US20170304427A1 RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FILOVIRUS VACCINE Public/Granted day:2017-10-26
Information query
